BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Oct. 7, 2003
View Archived Issues
Ingenium Broadens Relationship With Elan For Target Validation
Read More
Pennsylvania Biotech Incubators Rising From Tobacco Settlement
Read More
Other News To Note
Read More
Appointments And Advancements
Read More
BioVex Raises £17M, Aims For Phase II OncoVEX Trial
LONDON - BioVex Ltd. raised £17 million in third-round funding, giving it the means to start a U.S. Phase II trial of its lead cancer vaccine, OncoVEX, and move ImmunoVEX into Phase I work. (BioWorld Today)
Read More
Chiron, Patients Fight For Proleukin Reimbursement
Read More